

Thermal Cope reaction of 2-azetidinone-tethered 1,5-dienes: synthesis of tetrahydroazocinones

Pedro Almendros,^{a*} Cristina Aragoncillo,^b Gema Cabrero,^b Ricardo Callejo,^b Rocío Carrascosa,^b Amparo Luna,^b Teresa Martínez del Campo,^b M. Carmen Pardo,^b M. Teresa Quirós,^b M. Carmen Redondo,^b Carolina Rodríguez-Ranera,^b Alberto Rodríguez-Vicente,^b and M. Pilar Ruiz^b

^aInstituto de Química Orgánica General, CSIC, Juan de la Cierva 3, 28006-Madrid, Spain

^bDepartamento de Química Orgánica I, Facultad de Química, Universidad Complutense de Madrid, 28040-Madrid, Spain

E-mail: Palmendros@iqog.csic.es

Dedicated to Prof. Benito Alcaide on the occasion of his 60th birthday

Abstract

We report herein full details of the first example of a Cope rearrangement in which the C3–C4 bond of the β-lactam nucleus is the central bond of the 1,5-hexadiene system, thus providing an easy and efficient entry to novel, and in some cases optically pure functionalized azocinones.

Keywords: Azocinones, Cope reaction, β-lactams, rearrangements


Introduction

Eight-membered nitrogen heterocycles are constituents of a number of compounds with interesting pharmacological properties.¹ In particular, eight-membered-ring lactams (2-azocanones) are significant from a medicinal chemistry perspective. However, in contrast to their congeners with a smaller ring size, eight-membered-ring lactams are relatively rare structural motifs in natural products.² Tailored biologically active compounds of this type are mostly benzo-annulated or fused with other heterocycles.³ With at least one endocyclic C=C double bond (i.e. hexahydroazocinones), they adopt a conformation that makes them attractive peptide building blocks, since they are known to mimic a dipeptide β-turn.⁴ Unfortunately, cyclization to medium-sized heterocycles is often slow and is hampered by the unfavorable enthalpies (strain in medium rings) and entropies (probability of the chain ends meeting) of the reaction.⁵

On the other hand, the thermal $\pi^2s + \sigma^2s + \pi^2s$ (Cope) rearrangement of *cis*-1,2-divinylcyclobutane has been developed into a useful and widely applied tool for the synthesis of

cyclooctane derivatives.⁶ Driven by the release of cyclobutane ring strain, this Cope rearrangement often proceeds at significantly lower temperatures (60–140°C) than analogous reactions involving acyclic 1,5-dienes.

The 2-azetidinone (β -lactam) skeleton is well established as the key pharmacophore of β -lactam antibiotics, the most widely employed class of antibacterial agents.⁷ In addition, there are many important nonantibiotic uses of 2-azetidinones in fields ranging from enzyme inhibition⁸ to gene activation.⁹ Apart from their clinical interest, the use of β -lactams as versatile synthons for the preparation of compounds of biological relevance, such as α - and β -amino acids, alkaloids, heterocycles, and taxoids, is now well established.¹⁰ In spite of its synthetic potential, the behavior of the 2-azetidinone nucleus under thermal conditions remains still almost unknown.¹¹ Following our commitment in β -lactam and heterocyclic chemistry,¹² in this paper we report full details of the thermally induced [3,3] sigmatropic (Cope) rearrangement of β -lactams having alkenyl groups both at the C3 and C4 positions that fully confirms our earlier conclusions,¹³ and establishes a versatile route to a variety of racemic and enantiopure eight-membered lactams. A brief retrosynthetic analysis for the tetrahydroazocinone unit is illustrated in Scheme 1.




Scheme 1

Results and Discussion

Starting 4-formyl β -lactams **1** were prepared following literature methods.¹⁴ Rearrangement precursors, 2-azetidinone-tethered dienes **2–4**, were prepared both in the racemic and in optically pure forms using standard methodology. Racemic compounds **2a–h** were obtained as single *E*-isomers or as an *E/Z* mixture by Wittig olefination of racemic *cis*-4-formyl β -lactams **1a** and **1b** (Table 1). Racemic compounds **3a** and **3b** and enantiomerically pure divinyl- β -lactams **4** were prepared as single *cis*-diastereoisomers from the appropriate cinnamylideneimine, derived from benzylamine or *R*(+)- α -methylbenzylamine, respectively, through Staudinger reaction with the corresponding system acid chloride/triethylamine, in refluxing dichloromethane (Schemes 2 and 3).¹⁵ Compounds **4a** and **4b** were obtained as a mixture of diastereoisomers with opposite configuration at the C3 and C4 stereocenters of the β -lactam ring. These isomers were easily separated by flash chromatography. On the basis of the reported data for related β -lactam systems concerning the ^1H NMR chemical shift of the signal corresponding to the exocyclic methine proton H1' attached to N1, configuration (1'R, 3S, 4R) and (1'R, 3R, 4S) was assigned for


major (α) and minor (β) isomers, respectively.¹⁶ The preferred conformations together with the chemical shifts for protons H1' are depicted in Figure 1.

Table 1. Synthesis of 2-azetidinone-tethered dienes **2^a**





Aldehyde	R ¹	R ²	Diene	cis/trans	Z/E	Yield (%)
(\pm)- 1a	H	CO ₂ Me	(\pm)- 2a	100/-	-/100	82
(\pm)- 1b	Me	CO ₂ Me	(\pm)- 2b	100/-	-/100	92
(\pm)- 1a	H	COMe	(\pm)- 2c	100/-	-/100	68
(\pm)- 1b	Me	COMe	(\pm)- 2d	100/-	-/100	65
(\pm)- 1a	H	Ph	(\pm)- 2e	35/65	-/100	30/46 ^b
(\pm)- 1b	Me	Ph	(\pm)- 2f	85/15	40/60	91 ^c
(\pm)- 1a	H	CN	(\pm)- 2g	100/-	40/60	35/55 ^d
(\pm)- 1b	Me	CN	(\pm)- 2h	100/-	56/44	55/34 ^d


^a PMP = 4-MeOC₆H₄. The assignment of the *cis/trans* stereochemistry to β -lactams was based on the observed coupling constants for methine protons H3 and H4 (*cis* ca. 2.0 Hz; *trans* ca. 5.0 Hz). ^b Yields for isomers *cis* and *trans*, respectively. The reaction was carried out at room temperature. ^c Yields for the inseparable mixture of isomers *E-cis*, *Z-cis*, and *E-trans* (45:40:15). The reaction was carried out at room temperature. ^d Yields for chromatographically separable isomers *Z* and *E*, respectively.



Scheme 2

**Scheme 3****Figure 1**



Having obtained the starting substrates, the next stage was set to carry out the tetrahydroazocinone formation. In an initial reaction, a solution of diene **2a** in toluene was heated at 120°C in a sealed tube for 2 hours. Analysis by ^1H NMR spectroscopy revealed a quantitative conversion (>97%) to the desired tetrahydroazocinone **5a**. Next, we tried the same reaction in refluxing toluene, with similar results after 4 hours. According to the strategy outlined above, 2-azetidinone-tethered dienes **2–4** were thermally treated under the optimized conditions (sealed tube, 120 °C). To our delight, pure compounds **5a–l** were isolated in good to quantitative yields (60–100%) by flash chromatography. Table 2 summarizes our results for the different β -lactams tested.

Table 2. Synthesis of tetrahydroazocinones **5** through Cope reaction of *E-cis*-2-azetidinone-tethered dienes **2-4**^a


(E)-Diene	R ¹	R ²	R ³	Azocinone	t (h)	Yield (%)
(±)- 2a	H	CO ₂ Me	PMP	(±)- 5a	5	86
(±)- 2b	Me	CO ₂ Me	PMP	(±)- 5b	5	90
(±)- 2c	H	COMe	PMP	(±)- 5c	4	85
(±)- 2d	Me	COMe	PMP	(±)- 5d	3.5	87
(±)- 2e	H	Ph	PMP	(±)- 5e	5	70
(±)- 2f ^b	Me	Ph	PMP	(±)- 5f	4	60 ^c
(±)- 2g	H	CN	PMP	(±)- 5g	2	100
(±)- 2h	Me	CN	PMP	(±)- 5h	2	100
(±)- 3a	H	Ph	Bn	(±)- 5i	2.5	79
(±)- 3b	Me	Ph	Bn	(±)- 5j	4	79
(+)- 4a-α	H	Ph	(R)-CH(Me)Ph	(-)- 5k-α	4	82
(+)- 4a-β	H	Ph	(R)-CH(Me)Ph	(+)- 5k-β	4	75
(-)- 4b-α	Me	Ph	(R)-CH(Me)Ph	(-)- 5l-α	3	75
(+)- 4b-β	Me	Ph	(R)-CH(Me)Ph	(+)- 5l-β	3	83

^a PMP = 4-MeOC₆H₄. ^b Mixture of β-lactams *E-cis/Z-cis/E-trans*. ^c Yield assuming that only the *cis* isomer reacts.


Replacing the *E*-isomer by the *Z*-isomer on the alkene moiety substituted by the R² group in 2-azetidinone-tethered dienes **2** resulted in a remarkable loss of reactivity. When the *E* configuration was switched to *Z*, dienes **2g** and **2h** were converted into the corresponding tetrahydroazocinones **5g** and **5h** in quantitative yields only under harsher conditions (sealed tube, 150 °C, 3–6 h) (Scheme 4). The difference in reactivity of the *Z* and *E* isomers can be explained taking into account the higher steric and/or stereoelectronic interaction between the CN and PMP groups in the boat-like transition state for the *Z* isomer in comparison with the *E* isomer (Scheme 5).

**Scheme 4****Scheme 5**

Of particular interest were the reactions of enantiomerically pure substrates **4a**- α,β and **4b**- α,β which cleanly rearranged to the corresponding optically pure tetrahydroazocinones **5k**- α,β and **5l**- α,β , respectively (Table 2). Also, when a mixture of isomers (α/β) of substrates **4a** and **4b** was used, a mixture of the corresponding azocinones **5k**- α,β and **5l**- α,β was obtained in the same relative proportions. Moreover, isomeric mixture (α/β) of compound **5k,l** was more amenable to chromatographic purification than the corresponding precursors, isomeric dienes **4a,b**. Above results show, not unexpectedly, the stereospecificity of these Cope rearrangements (Scheme 6), which may be interpreted *via* a boat-like transition state.¹⁷

**Scheme 6**

Replacing the *cis*- β -lactam by the *trans*- β -lactam isomer in 2-azetidinone-tethered dienes **2** resulted in a remarkable loss of efficiency. For dienes *trans*-**2e** and *trans*-**3b**, the rearrangement did not proceed under standard conditions. The desired [3,3] sigmatropic (Cope) rearrangement of *trans*- β -lactam diene *trans*-**2e** took place not very efficiently on heating in toluene at 180 °C in sealed tube, affording the corresponding azocinone **5e** in a poor 30% yield (Scheme 7). The conversion of diene *trans*-**2e** into azocinone **5e** may involve an initial *trans/cis* isomerization through a diradical intermediate, followed by the Cope rearrangement of the *in situ* generated *cis*- β -lactam.

**Scheme 7**

Conclusions

The present study provides the first insight into the manner in which *cis*- β -lactams having alk-2-enyl groups both at the C3 and C4 positions undergo a thermally induced [3,3] sigmatropic (Cope) rearrangement to give new functionalized eight-membered lactam adducts (tetrahydroazocinones), in racemic as well as optically pure forms. This process involves a novel, concerted C3–C4 bond breakage of the β -lactam nucleus helped by ring strain.

Experimental Section

General Procedures. Melting points were measured by using a Gallen-kamp apparatus and are uncorrected. IR spectra were recorded with a Perkin-Elmer 781 spectrophotometer. ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker Avance-300, Varian VRX-300S or Bruker AC-200. NMR spectra were recorded in CDCl_3 solutions, except otherwise stated. Chemical shifts are given in ppm relative to TMS (^1H , 0.0 ppm), or CDCl_3 (^{13}C , 76.9 ppm). Mass spectra were recorded with a HP5989A spectrometer using the electronic impact (EI) method. Optical rotations were measured by using a Perkin-Elmer 241 polarimeter. Specific rotation $[\alpha]_D$ is given in 10^{-1} deg $\text{cm}^2 \text{ g}^{-1}$ at 20 °C, and the concentration (c) is expressed in g per 100 mL. Elemental analyses were obtained at the UCM Microanalysis Service (Facultad de Farmacia, UCM, 28040 Madrid). All commercially available compounds were used without further purification. Flash chromatography was performed by using Merck silica gel 60 (230–400 mesh). Products were identified by TLC (Kieselgel 60F-254). UV light ($\lambda = 254$ nm) and a solution of phosphomolybdic acid in EtOH (1g of phosphomolybdic acid hydrate, 100 mL EtOH) were used to develop the plates.

Preparation of dienes 2

Method A. To a solution of the appropriate 4-oxoazetidine-2-carbaldehyde **1** (1.0 mmol) in anhydrous THF (10 mL), under argon atmosphere, the corresponding phosphorane (1.40 mmol) was added portionwise and the mixture was heated at reflux temperature for 3 h. The reaction mixture was allowed to cool to room temperature and the solvent was removed under reduced pressure. Chromatography of the residue using ethyl acetate/hexanes gave the corresponding dienes **2**.

Method B. To a suspension of benzyltriphenylphosphonium bromide (1.6 mmol) in anhydrous THF (30 mL), under argon atmosphere, *n*BuLi (1.6 M in hexane, 1.40 mmol) was added dropwise. The red mixture was stirred for 20 min at room temperature and the appropriate 4-oxoazetidine-2-carbaldehyde **1** (1 mmol) in THF (10 mL) was added. The reaction was stirred for 3h and then was washed with NaCl (aq. sat.), the aqueous residue was extracted with AcOEt and the organic layer was dried (MgSO_4). The solvent was removed under reduced pressure.

Chromatography of the residue eluting with hexanes/ethyl acetate gave analytically pure dienes **2**.

Diene (\pm)-2a. Method A. From 100 mg (0.43 mmol) of 4-oxoazetidine-2-carbaldehyde (\pm)-**1a**, 100 mg (82%) of compound (\pm)-**2a** was obtained as a white solid after purification by flash chromatography (hexanes/ethyl acetate, 4:1). Mp 116–118 °C (hexanes/ethyl acetate). NMR data: δ_H (CDCl₃) 3.68 (s, 3H, OCH₃), 3.72 (s, 3H, OCH₃), 4.16 (t, 1H, J = 7.0 Hz, H3), 4.72 (t, 1H, J = 6.8 Hz, H4), 5.26–5.43 (m, 2H, C=CH₂), 5.67 (m, 1H, CH=CH₂), 6.01 (d, 1H, J = 15.8 Hz, CH-CO₂CH₃), 6.83 (m, 3H, CH=CH-CO₂CH₃, Ar), 7.21 (m, 2H, Ar). δ_C (CDCl₃) 165.4 (C=O), 163.8 (C2), 156.3 (Ar), 142.7, 130.8 (Ar), 127.9, 121.7 (CH=CH₂), 118.1 (Ar), 114.3 (Ar), 57.8 (C4), 55.7 (OCH₃), 55.4 (OCH₃), 51.7 (C3). IR (KBr, cm⁻¹): ν 1735 (NC=O), 1514 (C=O). Anal. Calcd for C₁₆H₁₇NO₄: C, 66.89; H, 5.96; N, 4.88. Found: C, 66.75; H, 6.12; N, 4.99.

Diene (\pm)-2b. Method A. From 302 mg (1.30 mmol) of 4-oxoazetidine-2-carbaldehyde (\pm)-**1b**, 345 mg (92%) of compound (\pm)-**2b** was obtained as a white solid after purification by flash chromatography (hexanes/ethyl acetate, 5:1). Mp 123–125 °C (hexanes/ethyl acetate). NMR data: δ_H (CDCl₃) 1.62 (s, 3H, CH₃), 3.67 (s, 3H, OCH₃), 3.71 (s, 3H, OCH₃), 4.09 (d, 1H, J = 6.0 Hz, H3), 4.67 (t, 1H, J = 6.8 Hz, H4), 5.03 (s, 1H, C=CH_H), 5.12 (s, 1H, C=CH_H), 6.04 (d, 1H, J = 15.8 Hz, CH-CO₂CH₃), 6.80 (m, 3H, CH=CH-CO₂CH₃, Ar), 7.22 (d, 2H, J = 8.7 Hz, Ar). δ_C (CDCl₃) 165.7 (C=O), 164.0 (C2), 156.4, 142.5 (C=CH₂), 135.9 (CH=CHCO₂CH₃), 131.1, 125.7 (CH=CHCO₂CH₃), 118.3, 116.8 (C=CH₂), 114.6, 60.8, 56.0 (OCH₃), 55.6 (OCH₃), 52.0, 22.6 (CH₃). IR (KBr, cm⁻¹): ν 1735 (NC=O), 1718 (C=O), 1515. Anal. Calcd for C₁₇H₁₉NO₄: C, 67.76; H, 6.36; N, 4.65. Found: C, 67.86; H, 6.22; N, 4.49.

Diene (\pm)-2c. Method A. From 470 mg (2.03 mmol) of 4-oxoazetidine-2-carbaldehyde (\pm)-**1a**, 375 mg (68%) of compound (\pm)-**2c** was obtained as a white solid after purification by flash chromatography (hexanes/ethyl acetate 4:1). Mp 117–119 °C (hexanes/ethyl acetate). NMR data: δ_H (CDCl₃) 2.20 (s, 3H, CH₃), 3.71 (s, 3H, OCH₃), 4.17 (dd, 1H, J = 6.2, 7.4 Hz, H3), 4.72 (dd, 1H, J = 6.2, 6.7 Hz, H4), 5.33 (m, 2H, C=CH₂), 5.65 (m, 1H, CH=CH₂), 6.24 (d, 1H, J = 16.2 Hz, CH-COCH₃), 6.66 (dd, 1H, J = 6.9, 16.2 Hz, CH=CH-COCH₃), 6.80 (d, 2H, J = 8.7 Hz, Ar), 7.22 (m, 2H, J = 8.7 Hz, Ar). δ_C (CDCl₃) 197.0 (C=O), 163.8 (C2), 156.4 (Ar), 141.3, 134.0, 131.0 (Ar), 128.0, 121.8 (CH=CH₂), 118.1 (Ar), 114.5 (Ar), 57.8, 56.0, 55.5, 27.6 (CH₃). IR (KBr, cm⁻¹): ν 1734 (NC=O), 1670 (C=O), 1518. Anal. Calcd for C₁₆H₁₇NO₃: C, 70.83; H, 6.32; N, 5.16. Found: C, 70.88; H, 6.19; N, 5.23.

Diene (\pm)-2d. Method A. From 100mg (0.43 mmol) of 4-oxoazetidine-2-carbaldehyde (\pm)-**1b**, 80 mg (65%) of compound (\pm)-**2d** was obtained as a white solid after purification by flash chromatography (hexanes/ethyl acetate 4:1). Mp 116–118 °C (hexanes/ethyl acetate). NMR data: δ_H (CDCl₃) 1.61 (s, 3H, CH₃), 2.18 (s, 3H, COCH₃), 3.71 (s, 3H, OCH₃), 4.11 (d, 1H, J = 6.0 Hz, H3), 4.67 (t, 1H, J = 6.8 Hz, H4), 5.04 (s, 1H, C=CH_H), 5.14 (s, 1H, C=CH_H), 6.28 (d, 1H, J = 15.8 Hz, CH-COCH₃), 6.64 (dd, 1H, J = 7.7, 15.8 Hz, CH=CH-COCH₃), 6.78 (d, 2H, J = 8.7 Hz, Ar), 7.25 (d, 2H, J = 8.7 Hz, Ar). δ_C (CDCl₃) 197.1 (C=O), 163.7 (C2), 156.4, 141.1 (C=CH₂), 136.0 (CH=CHCOCH₃), 134.6 (CH=CHCOCH₃), 131.1, 118.1, 116.6 (C=CH₂),

114.5, 60.7, 56.0, 55.5 (OCH_3), 27.3 (CH_3), 22.4 (CH_3). IR (KBr, cm^{-1}): ν 1732 (NC=O), 1672 (C=O), 1639, 1514. Anal. Calcd for $\text{C}_{17}\text{H}_{19}\text{NO}_3$: C, 71.56; H, 6.71; N, 4.91. Found: C, 71.45; H, 6.81; N, 5.07.

Diene (\pm)-2e. Method B. From 100 mg (0.43 mmol) of 4-oxoazetidine-2-carbaldehyde (\pm)-1a, and after purification by flash chromatography (hexanes/ethyl acetate 4:1), 40 mg (30%) of *E-cis*-(\pm)-2e and 60 mg (46%) of *E-trans*-(\pm)-2e were obtained.

Diene *E-cis*-(\pm)-2e. Colourless oil. NMR data: δ_{H} (CDCl_3) 3.69 (s, 3H, OCH_3), 4.12 (dd, 1H, J = 5.8, 7.4 Hz, H3), 4.72 (dd, 1H, J = 5.8, 8.2 Hz, H4), 5.31 (m, 2H, $\text{C}=\text{CH}_2$), 5.76 (m, 1H, $\text{CH}=\text{CH}_2$), 6.15 (dd, 1H, J = 8.2, 16.0 Hz, $\text{CH}=\text{CHPh}$), 6.76 (m, 3H, $\text{CH}=\text{CHPh}$, Ar), 7.31 (m, 7H, Ar). δ_{C} (CDCl_3) 164.8 (C2), 156.2 (Ar), 135.9, 135.4, 131.8, 129.1, 128.8, 128.5, 126.8, 125.1, 121.0, 118.5, 114.4, 58.0, 57.9, 55.6 (OCH_3). IR (CHCl_3 , cm^{-1}): ν 1740 (NC=O), 1512 (C=O). Anal. Calcd for $\text{C}_{20}\text{H}_{19}\text{NO}_2$: C, 78.66; H, 6.27; N, 4.59. Found: C, 78.55; H, 6.12; N, 4.42.

Diene *E-trans*-(\pm)-2e. Colourless oil. NMR data: δ_{H} (CDCl_3) 3.68 (m, 1H, H3), 3.69 (s, 3H, OCH_3), 4.35 (dd, 1H, J = 2.3, 8.4 Hz, H4), 5.27 (s, 2H, $\text{C}=\text{CH}$), 5.36 (s, 1H, $\text{C}=\text{CH}$), 5.95 (m, 1H, $\text{CH}=\text{CH}_2$), 6.22 (dd, 1H, J = 8.4, 16.0 Hz, $\text{CH}=\text{CHPh}$), 6.70 (m, 3H, $\text{CH}=\text{CHPh}$, Ar), 7.13–7.35 (m, 7H, Ar). δ_{C} (CDCl_3) 164.3 (C2), 156.0, 135.8, 134.9, 131.6, 129.3, 128.6, 128.5, 127.9, 127.9, 119.8, 118.2, 114.2, 61.1, 60.5, 55.6 (OCH_3). IR (CHCl_3 , cm^{-1}): ν 1743 (NC=O), 1510 (C=O). Anal. Calcd for $\text{C}_{20}\text{H}_{19}\text{NO}_2$: C, 78.66; H, 6.27; N, 4.59. Found: C, 78.53; H, 6.00; N, 4.71.

Diene (\pm)-2f. From 100 mg (0.43 mmol) of 4-oxoazetidine-2-carbaldehyde (\pm)-1b, 120 mg (91%) of an inseparable mixture of isomers *E-cis/Z-cis/E-trans* (45:50:15) were obtained as a colourless oil after purification by flash chromatography (hexanes/ethyl acetate 4:1). NMR data: δ_{H} (CDCl_3) 1.72 (s, 3H, CH_3), 1.84 (s, 3H, CH_3), 1.87 (s, 3H, CH_3 *E-trans*), 3.77 (s, 9H, OCH_3), 3.84 (d, 1H, J = 2.5 Hz, H3 *E-trans*), 4.13 (d, 1H, J = 6.1 Hz, H3 *E-cis*), 4.20 (d, 1H, J = 5.9 Hz, H3 *Z-cis*), 4.47 (dd, 1H, J = 2.4, 8.3 Hz, H4 *E-trans*), 4.76 (dd, 1H, J = 5.9, 8.8 Hz, H4 *E-cis*), 5.01 (bs, 1H, $\text{C}=\text{CH}$ *E-trans*), 5.09–5.15 (m, 4H, 3 $\text{C}=\text{CH}$, H4 *Z-cis*), 5.25 (bs, 2H, 2 $\text{C}=\text{CH}$), 5.77 (dd, 1H, J = 10.0, 11.7 Hz, $\text{CH}=\text{CHPh}$ *Z-cis*), 6.23 (dd, 1H, J = 8.8, 15.9 Hz, $\text{CH}=\text{CHPh}$ *E-cis*), 6.33 (dd, 1H, J = 8.3, 15.9 Hz, $\text{CH}=\text{CHPh}$ *E-trans*), 6.75–6.90 (m, 9H, $\text{CH}=\text{CHPh}$, PMP), 7.20–7.50 (m, 21H, Ph, PMP).

Diene (\pm)-2g. From 94 mg (0.41 mmol) of 4-oxoazetidine-2-carbaldehyde (\pm)-1a, and after purification by flash chromatography (hexanes/ethyl acetate 5:1), 36 mg (35%) of *Z-cis*-(\pm)-2g and 57 mg (55%) of *E-cis*-(\pm)-2g were obtained.

Diene *Z-cis*-(\pm)-2g. White solid. Mp 125–127 °C (hexanes/ethyl acetate). NMR data: δ_{H} (CDCl_3) 3.79 (s, 3H, OCH_3), 4.35 (bdd, 1H, J = 6.0, 7.3 Hz, H3), 5.11 (ddd, 1H, J = 0.8, 5.9, 9.7 Hz, H4), 5.40 (dd, 1H, J = 1.2, 10.3 Hz, $\text{CH}=\text{CH}$), 5.54 (dd, 1H, J = 1.3, 17.0 Hz, $\text{CH}=\text{CH}$), 5.72 (dd, 1H, J = 1.0, 11.0 Hz, $\text{CH}=\text{CN}$), 5.75 (ddd, 1H, J = 7.3, 10.3, 17.2 Hz, $\text{CH}=\text{CH}_2$), 6.54 (dd, 1H, J = 9.7, 11.0 Hz, $\text{CH}=\text{CH-CN}$), 6.88 (m, 2H, Ar), 7.28 (m, 2H, Ar). δ_{C} (CDCl_3) 163.4 (C2), 156.5, 150.4 ($\text{CH}=\text{CH-CN}$), 130.7, 127.2 ($\text{CH}=\text{CH}_2$), 122.2 (=CH₂), 118.0, 114.6 (CN), 114.5, 104.8 ($\text{CH}=\text{CH-CN}$), 57.5 (C3), 55.4 (OCH_3), 54.8 (C4). IR (KBr, cm^{-1}): ν 1740

(NC=O). Anal. Calcd for C₁₅H₁₄N₂O₂: C, 70.85; H, 5.55; N, 11.02. Found: C, 70.88; H, 5.69; N, 10.98.

Diene E-cis-(±)-2g. Colourless oil. NMR data: δ_H (CDCl₃) 3.80 (s, 3H, OCH₃), 4.26 (dd, 1H, *J* = 6.6, 7.1 Hz, H3), 4.78 (dt, 1H, *J* = 0.8, 6.6 Hz, H4), 5.42 (d, 1H, *J* = 10.1 Hz, CH=CHH), 5.49 (d, 1H, *J* = 17.0 Hz, CH=CHH), 5.60 (dd, 1H, *J* = 0.8, 16.5 Hz, CH=CN), 5.72 (ddd, 1H, *J* = 7.8, 10.1, 17.3 Hz, CH=CH₂), 6.71 (dd, 1H, *J* = 6.4, 16.5 Hz, CH=CH-CN), 6.88 (m, 2H, Ar), 7.26 (m, 2H, Ar). δ_C (CDCl₃) 163.4 (C2), 156.6, 149.3 (CH=CH-CN), 130.4, 127.4 (CH=CH₂), 122.6 (=CH₂), 118.1, 115.9 (CN), 114.6, 104.2 (CH=CH-CN), 58.0 (C3), 55.9 (C4), 55.5 (OCH₃). IR (CHCl₃, cm⁻¹): ν 1743 (NC=O). MS (EI), *m/z*: 255 (M⁺ + 1, 7), 254 (M⁺, 38), 171 (M⁺ - 83, 30), 149 (100).

Diene (±)-2h. From 137 mg (0.59 mmol) of 4-oxoazetidine-2-carbaldehyde (±)-1b, and after purification by flash chromatography (hexanes/ethyl acetate 3:1), 90 mg (57%) of Z-(±)-2h and 53 mg (55%) of E-(±)-2h were obtained.

Diene Z-(±)-2h. White solid. Mp 137–139 °C (hexanes/ethyl acetate). NMR data: δ_H (CDCl₃) 1.72 (s, 3H, CH₃), 3.79 (s, 3H, OCH₃), 4.26 (d, 1H, *J* = 5.9 Hz, H3), 5.10 (ddd, 1H, *J* = 0.8, 5.9, 9.9 Hz, H4), 5.14 (s, 1H, C=CHH), 5.26 (d, 1H, *J* = 1.0 Hz, C=CHH), 5.71 (dd, 1H, *J* = 0.8, 11.0 Hz, CH=CN), 6.54 (dd, 1H, *J* = 9.9, 11.0 Hz, CH=CH-CN), 6.88 (m, 2H, Ar), 7.30 (m, 2H, Ar). δ_C (CDCl₃) 163.4 (C2), 156.6, 150.4 (CH=CH-CN), 135.6 (C=CH₂), 130.8, 118.1, 116.7 (=CH₂), 114.6, 114.5 (CN), 104.9 (CH=CH-CN), 60.4 (C3), 55.5 (OCH₃), 54.6 (C4), 22.3 (CH₃). IR (KBr, cm⁻¹): ν 1742 (NC=O). MS (EI), *m/z*: 269 (M⁺ + 1, 6), 268 (M⁺, 29), 186 (M⁺ - 82, 44), 149 (100). Anal. Calcd for C₁₆H₁₆N₂O₂: C, 71.62; H, 6.01; N, 10.44. Found: C, 71.70; H, 5.99; N, 10.48.

Diene E-(±)-2h. White solid. Mp 112–114 °C (hexanes/ethyl acetate). NMR data: δ_H (CDCl₃). NMR data: δ_H (CDCl₃) 1.70 (s, 3H, CH₃), 3.79 (s, 3H, OCH₃), 4.19 (d, 1H, *J* = 6.0 Hz, H3), 4.73 (td, 1H, *J* = 1.0, 6.6 Hz, H4), 5.15 (s, 1H, C=CHH), 5.19 (d, 1H, *J* = 0.9 Hz, C=CHH), 5.64 (dd, 1H, *J* = 1.0, 16.4 Hz, CH=CN), 6.70 (dd, 1H, *J* = 7.0, 16.4 Hz, CH=CH-CN), 6.87 (m, 2H, Ar), 7.26 (m, 2H, Ar). δ_C (CDCl₃) 163.3 (NC=O), 156.6, 148.8 (CH=CH-CN), 135.3 (C=CH₂), 130.5, 118.1, 117.2 (=CH₂), 115.9 (CN), 114.5, 104.5 (CH=CH-CN), 61.0 (C3), 55.9 (C4), 55.5 (OCH₃), 22.4 (Me). IR (KBr, cm⁻¹): ν 1743 (NC=O). Anal. Calcd for C₁₆H₁₆N₂O₂: C, 71.62; H, 6.01; N, 10.44. Found: C, 71.65; H, 6.10; N, 10.50.

Preparation of dienes 3. A suspension of benzylamine (10 mmol), cynamaldehyde (10 mmol) and magnesium sulphate (80 mmol) in dichloromethane (100 mL) was stirred at room temperature for 12 h. The resulting imine was filtered and the solvent was removed under reduced pressure. The corresponding imine was dissolved in dichloromethane (100 mL) and Et₃N (20 mmol) was added dropwise followed by the corresponding acid chloride (12 mmol) and the resulting mixture was refluxed for 5 h. The reaction was allowed to cool to room temperature and the crude mixture was washed with water (50 mL) and the aqueous layer was extracted with dichloromethane. The organic layer was dried (MgSO₄) and concentrated under reduced pressure. Chromatography of the residue eluting with hexanes/ethyl acetate gave analytically pure compounds 3.

Diene *cis*-(\pm)-3a. From 1.07 g (10 mmol) of benzylamine, 1.32 g of cynamaldehyde (10 mmol) and 1.14 mL (12 mmol) of crotonyl chloride, 1.60 g (56%) of compound (\pm)-3a was obtained as a colourless oil after purification by flash chromatography (hexanes/ethyl acetate 4:1) NMR data: δ_H (CDCl₃) 4.08 (m, 2H, H3, NCHH), 4.23 (dd, 1H, J = 5.6, 8.8 Hz, H4), 4.69 (d, 1H, J = 14.9 Hz, NCHH), 5.25-5.46 (m, 2H, C=CH₂), 5.81 (m, 1H, CH=CH₂), 6.02 (dd, 1H, J = 8.8, 15.9 Hz, CH=CHPh), 6.53 (d, 1H, J = 15.9 Hz, CH=CHPh), 7.25 (m, 10H, Ar). δ_C (CDCl₃) 167.6 (C2), 135.9, 135.8, 135.5, 129.2, 128.8, 128.6, 128.5, 128.2, 127.7, 126.6, 124.7, 120.3 (CH=CH₂), 58.1, 57.7, 44.6 (NCH₂). IR (CHCl₃, cm⁻¹): ν 1743 (NC=O). Anal. Calcd for C₂₀H₁₉NO: C, 83.01; H, 6.62; N, 4.84. Found: C, 80.18; H, 6.54; N, 5.03.

Diene (\pm)-3b. From 353 mg (3.3 mmol) of benzylamine, 397 mg (3.3 mmol) of cynamaldehyde and 0.44 mL (4 mmol) of 3,3-dimethylacryloyl chloride, 540 mg (54%) of isomer *cis*-(\pm)-3b and 30 mg (3%) of isomer *trans*-(\pm)-3b were obtained, after purification by flash chromatography (hexanes/ethyl acetate 4:1).

Diene *cis*-(\pm)-3b. Colourless oil. NMR data: δ_H (CDCl₃) 1.56 (s, 3H, CH₃), 3.89 (d, 1H, J = 5.4 Hz, H3), 3.99 (d, 1H, J = 15.2 Hz, NCHH), 4.11 (dd, 1H, J = 5.4, 9.3 Hz, H4), 4.59 (d, 1H, J = 15.2 Hz, NCHH), 4.98 (s, 1H, C=CHH), 5.12 (s, 1H, C=CHH), 5.91 (dd, 1H, J = 9.3, 15.6 Hz, CH=CHPh), 6.46 (d, 1H, J = 15.6 Hz, CH=CHPh), 7.22 (m, 10H, Ar). δ_C (CDCl₃) 167.6 (C2), 137.4, 136.2, 136.1, 135.9, 128.9, 128.8, 128.6, 128.3, 127.8, 126.7, 124.5, 115.0 (C=CH₂), 60.9 (C3), 57.7 (C4), 44.5 (NCH₂), 22.5 (CH₃). IR (CHCl₃, cm⁻¹): ν 1749 (NC=O). Anal. Calcd for C₂₁H₂₁NO: C, 83.13; H, 6.98; N, 4.62. Found: C, 82.95; H, 7.18; N, 4.88.

Diene *trans*-(\pm)-3b. Colourless oil. NMR data: δ_H (CDCl₃) 1.76 (s, 3H, CH₃), 3.63 (bs, 1H, H3), 3.90 (dd, 1H, J = 2.2, 8.7 Hz, H4), 4.03 (d, 1H, J = 15.0 Hz, NCHH), 4.74 (d, 1H, J = 15.0 Hz, NCHH), 4.93 (s, 1H, C=CHH), 5.00 (s, 1H, C=CHH), 6.10 (dd, 1H, J = 8.7, 15.8 Hz, CH=CHPh), 6.55 (d, 1H, J = 15.8 Hz, CH=CHPh), 7.31 (m, 10H, Ar). δ_C (CDCl₃) 167.5 (C2), 138.5, 136.1, 136.0, 134.7, 128.9, 128.9, 128.7, 128.5, 127.9, 126.8, 126.7, 114.3 (C=CH₂), 64.6 (C3), 59.2 (C4), 44.8 (NCH₂), 20.5 (CH₃). IR (CHCl₃, cm⁻¹): ν 1747 (NC=O). Anal. Calcd for C₂₁H₂₁NO: C, 83.13; H, 6.98; N, 4.62. Found: C, 82.99; H, 7.12; N, 4.85.

Preparation of dienes 4. A mixture of (*R*)-1-phenylethylamine (10 mmol), cynamaldehyde (10 mol) and crotonyl chloride (for 4a) or 3,3-dimethylacryloyl (for 4b) in anhydrous dichloromethane (100 mL) was stirred for 5 h at room temperature. The crude mixture was washed with water (50 mL) and the aqueous layer was extracted with dichloromethane. The organic layer was dried (MgSO₄) and concentrated under reduced pressure. Chromatography of the residue eluting with hexanes/ethyl acetate (5:1) gave analytically pure 1.85 g (61%) of compound 4a as a mixture of diastereomers (56:44) and 1.80 g (57%) of compound 4b, as a mixture of diastereomers (64:36). Diastereomers were separated after a second flash chromatography using hexanes/ethyl acetate (3:1).

Diene (+)-4a- α . Colourless oil (34%). $[\alpha]_D = +95.0$ (c 1.0, CHCl₃). NMR data: δ_H (CDCl₃) 1.51 (d, 3H, J = 7.2 Hz, CH₃), 3.84 (dd, 1H, J = 5.8, 7.2 Hz, H3), 4.05 (m, 1H, H4), 4.92 (q, 1H, J = 7.2 Hz, NCH), 5.27 (m, 2H, C=CH₂), 5.70 (m, 1H, CH=CH₂), 6.03 (dd, 1H, J = 6.5, 15.8 Hz, CH=CHPh), 6.37 (d, 1H, J = 15.8 Hz, CH=CHPh), 7.22 (m, 10H, Ar). δ_C (CDCl₃) 167.2 (C2),

140.2, 136.0, 134.4, 129.4, 128.6, 128.6, 128.2, 127.7, 127.3, 126.7, 126.6, 120.2 ($\text{CH}=\text{CH}_2$), 57.6, 57.4, 51.9 (NCH), 19.5 (CH_3). IR (CHCl_3 , cm^{-1}): ν 1740 (NC=O). Anal. Calcd for $\text{C}_{21}\text{H}_{21}\text{NO}$: C, 83.13; H, 6.98; N, 4.62. Found: C, 83.24; H, 7.11; N, 4.51.

Diene (+)-4a- β . Colourless oil (27%). $[\alpha]_D = +325.0$ (c 1.0, CHCl_3). NMR data: δ_{H} (CDCl_3) 1.65 (d, 3H, $J = 7.2$ Hz, CH_3), 3.90 (dd, 1H, $J = 5.6, 7.2$ Hz, H3), 4.18 (dd, 1H, $J = 5.6, 9.1$ Hz, H4), 4.61 (q, 1H, $J = 7.2$ Hz, NCH), 5.22 (m, 2H, $\text{CH}=\text{CH}_2$), 5.60–5.77 (m, 2H, $\text{CH}=\text{CH}_2$, $\text{CH}=\text{CHPh}$), 6.37 (d, 1H, $J = 15.8$ Hz, $\text{CH}=\text{CHPh}$), 7.20 (m, 10H, Ar). δ_{C} (CDCl_3) 167.2 (C2), 141.3, 135.8, 134.7, 129.2, 128.4, 128.4, 128.0, 127.4, 126.8, 126.4, 125.4, 120.0 ($\text{CH}=\text{CH}_2$), 57.1, 57.0, 52.7 (NCH), 18.7 (CH_3). IR (CHCl_3 , cm^{-1}): ν 1739 (NC=O), 1494. MS (EI), m/z : 304 ($\text{M}^+ + 1$, 2), 303 (M^+ , 6), 199 ($\text{M}^+ - 104$, 86), 105 (100). Anal. Calcd for $\text{C}_{21}\text{H}_{21}\text{NO}$: C, 83.13; H, 6.98; N, 4.62. Found: C, 83.26; H, 7.05; N, 4.45.

Diene (-)-4b- α . Colourless oil (37%). $[\alpha]_D = -117.0$ (c 1.1, CHCl_3). NMR data: δ_{H} (CDCl_3) 1.59 (d, 3H, $J = 7.4$ Hz, $\text{CHPh}-\text{CH}_3$), 1.61 (s, 3H, CH_3), 3.84 (d, 1H, $J = 5.6$ Hz, H3), 4.10 (dd, 1H, $J = 5.6, 9.4$ Hz, H4), 5.04 (q, 1H, $J = 7.0$ Hz, NCH), 5.05 (s, 1H, $\text{C}=\text{CHH}$), 5.19 (s, 1H, $\text{C}=\text{CHH}$), 6.08 (dd, 1H, $J = 9.4, 15.8$ Hz, $\text{CH}=\text{CHPh}$), 6.47 (d, 1H, $J = 15.8$ Hz, $\text{CH}=\text{CHPh}$), 7.32 (m, 10H, Ar). δ_{C} (CDCl_3) 167.0 (C2), 140.0, 137.3, 136.1, 134.5, 128.6, 128.3, 128.0, 127.6, 127.2, 126.5, 126.3, 114.7 ($\text{C}=\text{CH}_2$), 59.9, 57.3, 51.6 (NCH), 22.3 (CH_3), 19.5 (CH_3). IR (CHCl_3 , cm^{-1}): ν 1750 (NC=O). Anal. Calcd for $\text{C}_{21}\text{H}_{21}\text{NO}$: C, 83.24; H, 7.30; N, 4.41. Found: C, 83.37; H, 7.17; N, 4.61.

Diene (+)-4b- β . Colourless oil (20%). $[\alpha]_D = +85.0$ (c 0.8, CHCl_3). NMR data: δ_{H} (CDCl_3) 1.53 (s, 3H, CH_3), 1.65 (d, 3H, $J = 7.2$ Hz, $\text{CHPh}-\text{CH}_3$), 3.81 (d, 1H, $J = 5.6$ Hz, H3), 4.14 (dd, 1H, $J = 5.6, 9.4$ Hz, H4), 4.60 (c, 1H, $J = 7.2$ Hz, NCH), 5.10 (s, 1H, $\text{C}=\text{CHH}$), 5.22 (s, 1H, $\text{C}=\text{CHH}$), 5.76 (dd, 1H, $J = 9.4, 15.9$ Hz, $\text{CH}=\text{CHPh}$), 6.40 (d, 1H, $J = 15.9$ Hz, $\text{CH}=\text{CHPh}$), 7.25 (m, 10H, Ar). δ_{C} (CDCl_3) 167.1 (C2), 141.5, 137.3, 136.0, 135.1, 128.5, 128.5, 128.0, 127.4, 126.9, 126.5, 125.2, 114.7 ($\text{CH}=\text{CH}_2$), 59.8, 57.0, 52.6 (NCH), 22.4 (CH_3), 18.8 (CH_3). IR (CHCl_3 , cm^{-1}): ν 1738 (NC=O). Anal. Calcd for $\text{C}_{22}\text{H}_{23}\text{NO}$: C, 83.24; H, 7.30; N, 4.41. Found: C, 83.46; H, 7.16; N, 4.55.

Preparation of azocin-2-ones 5. A solution of the corresponding dialkenyl- β -lactam (1.0 mmol) in anhydrous toluene (5 mL) was heated in a sealed tube at 120 °C until complete disappearance of the starting material (TLC). The reaction was allowed to cool to room temperature, the solvent was removed under reduced pressure, and after purification by flash chromatography compounds **5** were obtained.

Azocin-2-one (\pm)-5a. From 70 mg (0.24 mmol) of compound (\pm)-**2a**, 60 mg (86%) of compound (\pm)-**5a** was obtained as a colourless oil after purification by flash chromatography (hexanes/ethyl acetate 5:1) NMR data: δ_{H} (CDCl_3) 2.34 (bs, 1H, $J = 14.0$ Hz, H5), 2.75 (bs, 1H, $J = 14.0$ Hz, H5'), 3.69 (s, 3H, OCH_3), 3.73 (s, 3H, OCH_3), 3.75 (m, 1H, H6), 5.71 (dd, 1H, $J = 7.6, 9.3$ Hz, H7), 5.85 (ddd, 1H, $J = 2.7, 5.4, 13.2$ Hz, H4), 6.09 (dt, 1H, $J = 2.2, 13.2$ Hz, H3), 6.19 (d, 1H, $J = 7.6$ Hz, H8), 6.84 (m, 2H, Ar), 7.14 (m, 2H, Ar). δ_{C} (CDCl_3) 173.2 (C=O), 167.1 (C2), 158.3, 132.0, 131.0, 130.2, 127.2, 124.1, 123.4, 114.2, 55.4, 52.4, 39.4, 32.5. IR (CHCl_3 , cm^{-1}): ν 1735 (NC=O), 1664 (C=O), 1624, 1607, 1510, 1248. MS (EI), m/z : 288 (M^+

+1, 24), 287 (M^+ , 82), 228 ($M^+ - 59$, 97), 134 (100). Anal. Calcd for $C_{16}H_{17}NO_4$: C, 66.89; H, 5.96; N, 4.88. Found: C, 66.96; H, 5.84; N, 4.99.

Azocin-2-one (\pm)-5b. From 33 mg (0.11 mmol) of compound (\pm)-2b, 30 mg (89%) of compound (\pm)-5b was obtained as a colourless oil after purification by flash chromatography (hexanes/ethyl acetate 3:1). NMR data: δ_H (DMSO, 70 °C) 1.81 (s, 3H, CH_3), 2.41 (bs, 1H, H5), 2.67 (bs, 1H, $J = 15.6$ Hz, H5'), 3.63 (m, 1H, H6), 3.69 (s, 3H, OCH_3), 3.76 (s, 3H, OCH_3), 5.60 (t, 1H, $J = 8.1$ Hz, H7), 5.84 (bs, 1H, H3), 6.19 (d, 1H, $J = 6.8$ Hz, H8), 6.95 (m, 2H, Ar), 7.16 (m, 2H, Ar). δ_C ($CDCl_3$) 176.1 (C=O), 167.4 (C2), 158.2, 138.9, 132.1, 130.6, 127.2, 123.3, 120.2, 114.1, 55.3, 52.2, 39.5, 37.2, 25.7 (CH_3). IR ($CHCl_3$, cm^{-1}): ν 1736 (NC=O), 1664 (C=O), 1624, 1508, 1248. MS (EI), m/z : 301 (M^+ , 40), 286 (2), 242 (65), 134 (100). Anal. Calcd for $C_{17}H_{19}NO_4$: C, 67.76; H, 6.36; N, 4.65. Found: C, 67.57; H, 6.44; N, 4.49.

Azocin-2-one (\pm)-5c. From 100 mg (0.37 mmol) of compound (\pm)-2c, 85 mg (85%) of compound (\pm)-5c was obtained as a white solid after purification by flash chromatography (hexanes/ethyl acetate 4:1). Mp 115–117 °C (hexanes/ethyl acetate). NMR data: δ_H ($CDCl_3$) 2.20 (m, 1H, H5), 2.21 (s, 3H, CH_3), 2.65 (bd, 1H, $J = 15.7$ Hz, H5'), 3.75 (s, 3H, OCH_3), 3.79 (m, 1H, H6), 5.55 (dd, 1H, $J = 7.6$, 9.5 Hz, H7), 5.81 (ddd, 1H, $J = 2.9$, 5.4, 13.0 Hz, H4), 6.02 (dt, 1H, $J = 2.1$, 13.2 Hz, H3), 6.16 (d, 1H, $J = 7.6$ Hz, H8), 6.86 (m, 2H, Ar), 7.15 (m, 2H, Ar). δ_C ($CDCl_3$) 206.9 (C=O), 167.4 (C2), 158.4, 132.1, 131.6, 130.6, 127.1, 124.3, 123.3, 114.4, 55.5, 46.7, 31.4 (C5), 29.3 (CH_3). IR ($CHCl_3$, cm^{-1}): ν 1707 (NC=O), 1662 (C=O), 1630, 1512, 1244. Anal. Calcd for $C_{16}H_{17}NO_3$: C, 70.83; H, 6.32; N, 5.16. Found: C, 70.67; H, 6.45; N, 5.29.

Azocin-2-one (\pm)-5d. From 60 mg (0.21 mmol) of compound (\pm)-2d, 52 mg (87%) of compound (\pm)-5d was obtained as a colourless oil after purification by flash chromatography (hexanes/ethyl acetate 4:1). NMR data: δ_H ($CDCl_3$) 1.78 (s, 3H, CH_3), 2.10 (bs, 1H, H5), 2.20 (s, 3H, $COCH_3$), 2.59 (bd, 1H, $J = 16.4$ Hz, H5'), 3.74 (m, 1H, H6), 3.74 (s, 3H, OCH_3), 5.54 (t, 1H, $J = 8.8$ Hz, H7), 5.87 (s, 1H, H3), 6.12 (d, 1H, $J = 7.6$ Hz, H8), 6.85 (m, 2H, Ar), 7.13 (m, 2H, Ar). δ_C ($CDCl_3$) 207.1 (C=O), 167.8 (C2), 158.3, 139.5, 132.2, 131.3, 127.1, 123.4, 120.3, 114.3, 55.4 (OCH_3), 50.0, 35.9, 29.6 (CH_3), 29.2 (CH_3). IR ($CHCl_3$, cm^{-1}): ν 1714 (NC=O), 1668 (C=O), 1625, 1604, 1508, 1245. Anal. Calcd for $C_{17}H_{19}NO_3$: C, 78.97; H, 6.63; N, 4.39. Found: C, 78.76; H, 6.74; N, 4.41.

Azocin-2-one (\pm)-5e. From 50 mg (0.16 mmol) of compound *cis*-(\pm)-2e, 35 mg (70 %) of compound (\pm)-5e was obtained as a colourless oil after purification by flash chromatography (hexanes/ethyl acetate 4:1). From compound *trans*-(\pm)-2e, 19 mg (37%) of compound (\pm)-5e was obtained. NMR data: δ_H ($CDCl_3$) 2.50 (bs, 1H, H5), 2.77 (bd, 1H, $J = 15.1$ Hz, H5'), 3.81 (s, 3H, OCH_3), 4.13 (bs, 1H, H6), 5.68 (t, 1H, $J = 9.3$ Hz, H7), 5.94 (m, 1H, H4), 6.16 (m, 2H, H3, H8), 6.92 (m, 2H, Ar), 7.25 (m, 7H, Ar). δ_C ($CDCl_3$) 167.8 (C2), 158.3, 142.7, 129.0, 129.0, 128.9, 127.3, 127.0, 127.0, 126.9, 126.8, 124.3, 114.3, 55.5 (OCH_3), 39.6, 36.8 (C5). IR ($CHCl_3$, cm^{-1}): ν 1735 (C=O), 1622 (C=O), 1510. MS (EI), m/z : 306 ($M^+ + 1$, 23), 305 (M^+ , 74), 236 (100). Anal. Calcd for $C_{20}H_{19}NO_2$: C, 78.66; H, 6.27; N, 4.59. Found: C, 78.58; H, 6.14; N, 4.45.

Azocin-2-one (\pm)-5f. From 100 mg (0.31 mmol) of the mixture of isomers (\pm)-2f, 60 mg (60 %) of compound (\pm)-5f was obtained as a colourless oil after purification by flash chromatography

(hexanes/ethyl acetate 3:1). NMR data: δ_H ($CDCl_3$) 1.90 (s, 3H, CH_3), 2.35 (bs, 1H, H5), 2.75 (bs, 1H, H5'), 3.81 (s, 3H, OCH_3), 4.11 (bs, 1H, H6), 5.69 (bs, 1H, H7), 5.99 (s, 1H, H3), 6.10 (d, 1H, $J = 7.8$ Hz, H8), 6.92 (m, 2H, PMP), 7.20–7.40 (m, 7H, Ar). δ_C ($CDCl_3$) 168.2 (C2), 158.3, 142.7, 140.5, 132.6, 129.5, 128.9, 128.6, 127.2, 127.0, 120.3, 114.3, 55.5 (OCH_3), 41.9, 39.2, 26.2. IR ($CHCl_3$, cm^{-1}): ν 1710 (C=O), 1664, 1622, 1508, 1246. MS (EI), m/z : 320 ($M^+ + 1$, 28), 319 (M^+ , 82), 304 ($M^+ - 15$, 24), 236 (100). Anal. Calcd for $C_{21}H_{21}NO_2$: C, 78.97; H, 6.63; N, 4.39. Found: C, 79.09; H, 6.55; N, 4.52.

Azocin-2-one (\pm)-5g. From 51 mg (0.20 mmol) of compound *E*-(\pm)-2g, 51 mg (quantitative yield) of compound (\pm)-5g was obtained as a white solid after purification by flash chromatography (hexanes/ethyl acetate 3:1). From *Z*-(\pm)-2g, 51 mg (quantitative yield) of compound (\pm)-5g was obtained. Mp 135–137 °C (hexanes/ethyl acetate). NMR data: δ_H ($CDCl_3$) 2.56 (dddd, 1H, $J = 1.5, 5.4, 12.7, 18.3$ Hz, H5), 2.94 (ddt, 1H, $J = 2.4, 4.4, 18.3$ Hz, H5'), 3.82 (s, 3H, OCH_3), 3.95 (ddd, 1H, $J = 4.1, 9.3, 12.7$ Hz, H6), 5.59 (dd, 1H, $J = 7.6, 9.3$ Hz, H7), 5.81 (ddd, 1H, $J = 2.9, 5.4, 13.1$ Hz, H4), 6.13 (dt, 1H, $J = 2.0, 13.1$ Hz, H3), 6.28 (dd, 1H, $J = 1.0, 7.6$ Hz, H8), 6.94 (m, 2H, Ar), 7.19 (m, 2H, Ar). δ_C ($CDCl_3$) 166.3 (C2), 158.8, 132.8 (C4), 131.4, 127.9 (C8), 127.2, 124.9 (C3), 124.8 (CN), 119.5 (C7), 114.5, 55.5 (OCH_3), 33.3 (C5), 25.7 (C6). MS (EI), m/z : 255 ($M^+ + 1$, 17), 254 (M^+ , 85), 134 (100). IR (KBr, cm^{-1}): ν 1735 (C=O). Anal. Calcd for $C_{15}H_{14}N_2O_2$: C, 70.85; H, 5.55; N, 11.02. Found: C, 70.90; H, 5.39; N, 10.98.

Azocin-2-one (\pm)-5h. From 31 mg (0.12 mmol) of compound *E*-(\pm)-2h, 31 mg (quantitative yield) of compound (\pm)-5h was obtained as a white solid after flash chromatography (hexanes/ethyl acetate 3:1). From *Z*-(\pm)-2h, 31 mg of compound (\pm)-5h (quantitative yield). Mp 162–164 °C (hexanes/ethyl acetate). NMR data: δ_H ($CDCl_3$) 1.86 (s, 3H, CH_3), 2.61 (dd, 1H, $J = 12.2, 16.6$ Hz, H5), 2.85 (dd, 1H, $J = 4.9, 16.6$ Hz, H5'), 3.79 (s, 3H, OCH_3), 4.06 (ddd, 1H, $J = 4.1, 8.3, 12.2$ Hz, H6), 5.58 (t, 1H, $J = 8.1$ Hz, H7), 5.90 (bs, 1H, H3), 6.30 (d, 1H, $J = 7.8$ Hz, H8), 6.97 (m, 2H, Ar), 7.22 (m, 2H, Ar). δ_C ($CDCl_3$) 166.8 (C2), 158.8, 137.2 (C4), 132.7 (C8), 131.6, 129.0 (C3), 127.3, 121.1 (C7), 119.5 (CN), 114.5, 55.5 (OCH_3), 37.7 (C5), 26.0 (CH_3), 25.3 (C6). IR ($CHCl_3$, cm^{-1}): ν 1735 (C=O). MS (EI), m/z : 269 ($M^+ + 1$, 17), 268 (M^+ , 78), 253 ($M^+ - 15$, 10), 134 (100). Anal. Calcd for $C_{16}H_{16}N_2O_2$: C, 71.62; H, 6.01; N, 10.44. Found: C, 71.55; H, 6.11; N, 10.39.

Azocin-2-one (\pm)-5i. From 210 mg (0.73 mmol) of compound (\pm)-3a, 165 mg (79%) of compound (\pm)-5i was obtained as a white solid after flash chromatography (hexanes/ethyl acetate 5:1). Mp 73–75 °C (hexanes/ethyl acetate). NMR data: δ_H ($CDCl_3$) 2.44 (bs, 1H, H5), 2.60 (bs, 1H, H5'), 3.56 (bs, 1H, H6), 4.09 (d, 1H, $J = 11.5$ Hz, NCHH), 5.32 (m, 1H, NCHH), 5.44 (t, 1H, $J = 7.8$ Hz, H7), 5.80–6.10 (m, 3H, H3, H4, H8), 6.69 (bs, 2H, Ar), 7.10–7.50 (m, 8H, Ar). δ_C ($CDCl_3$) 167.4 (C2), 142.3, 136.5, 132.0, 130.8, 129.1, 128.6, 128.4, 127.6, 126.8, 126.6, 125.2, 123.7, 50.3, 39.1, 35.9. IR (KBr, cm^{-1}): ν 1656 (C=O), 1612, 1598, 1492, 1423, 1259. Anal. Calcd for $C_{20}H_{19}NO$: C, 83.01; H, 6.62; N, 4.84. Found: C, 82.92; H, 6.70; N, 4.63.

Azocin-2-one (\pm)-5j. From 194 mg (0.63 mmol) of compound (\pm)-3b, 155 mg (80%) of compound (\pm)-5j was obtained as a white solid after flash chromatography (hexanes/ethyl acetate

5:1). Mp 109–111 °C (hexanes/ethyl acetate). NMR data: δ_H (CDCl₃) 1.80 (s, 3H, CH₃), 2.33 (d, 1H, *J* = 13.9 Hz, H5), 2.51 (m, 1H, H5'), 3.52 (m, 1H, H6), 4.67 (m, 2H, NCH₂Ph), 5.38 (t, 1H, *J* = 8.1 Hz, H7), 5.80 (s, 1H, H3), 6.05 (d, 1H, *J* = 8.1 Hz, H8), 6.85 (m, 2H, Ar), 7.15 (m, 3H, Ar), 7.30 (m, 5H, Ar). δ_C (CDCl₃) 167.5 (C2), 142.4, 140.5, 136.6, 130.6, 129.1, 128.6, 128.4, 128.4, 127.5, 126.8, 126.5, 119.9, 50.2 (NCH₂), 41.0, 39.2, 26.3. IR (CHCl₃, cm⁻¹): ν 1728 (NC=O), 1662 (C=O), 1610, 1255. Anal. Calcd for C₂₁H₂₁NO: C, 83.13; H, 6.98; N, 4.62. Found: C, 83.02; H, 7.10; N, 4.59.

Azocin-2-one (-)-5k- α . From 110 mg (0.36 mmol) of compound (+)-4a- α , 90 mg (82%) of compound (-)-5k- α was obtained as a colourless oil after flash chromatography (hexanes/ethyl acetate 5:1). [α]_D = -188 (*c* 1.0, CHCl₃). NMR data: δ_H (CDCl₃) 1.58 (d, 3H, *J* = 7.6 Hz, CH₃), 2.42 (m, 1H, H5), 2.74 (bd, 1H, *J* = 18.6 Hz, H5'), 3.97 (m, 1H, H6), 5.61 (m, 2H, CH₃CHPh, H7), 5.84 (m, 1H, H4), 5.99–6.07 (m, 1H, H3), 6.12 (q, 1H, *J* = 7.6 Hz, H8), 7.32 (m, 10H, Ar). δ_C (CDCl₃) 167.2 (C2), 142.6, 139.0, 131.5, 131.2, 128.7, 128.3, 127.6, 127.5, 127.1, 126.8, 124.5, 124.0, 51.1, 39.2, 36.5, 16.0. IR (CHCl₃, cm⁻¹): ν 1743 (C=O), 1712, 1658, 1601. MS (EI), *m/z*: 304 (M⁺ + 1, 3), 303 (M⁺, 1), 288 (1), 105 (100). Anal. Calcd for C₂₁H₂₁NO: C, 83.13; H, 6.98; N, 4.62. Found: C, 83.22; H, 6.70; N, 4.59.

Azocin-2-one (+)-5k- β . From 50 mg (0.16 mmol) of compound (+)-4a- β , 40 mg (75%) of compound (+)-5k- β was obtained as a colourless oil after flash chromatography (hexanes/ethyl acetate 5:1). [α]_D = +155 (*c* 1.0, CHCl₃). NMR data: δ_H (CDCl₃) 1.59 (d, 3H, *J* = 7.8 Hz, CH₃), 2.33 (m, 1H, H5), 2.58 (bd, 1H, *J* = 17.8 Hz, H5'), 3.38 (m, 1H, H6), 5.46 (t, 1H, *J* = 9.5 Hz, H7), 5.80 (m, 1H, H4), 5.95–6.13 (m, 3H, H3, H8, CH₃CHPh), 6.60 (m, 2H, Ar), 7.15–7.45 (m, 8H, Ar). δ_C (CDCl₃) 167.2 (C2), 142.3, 132.9, 131.3, 128.4, 128.3, 127.7, 127.5, 127.1, 127.0, 126.6, 124.2, 123.8, 51.7, 38.8, 35.8, 15.9. IR (CHCl₃, cm⁻¹): ν 1735 (C=O), 1718, 1659, 1601. Anal. Calcd for C₂₁H₂₁NO: C, 83.13; H, 6.98; N, 4.62. Found: C, 83.25; H, 6.81; N, 4.53.

Azocin-2-one (-)-5l- α . From 80 mg (0.25 mmol) of compound (-)-4b- α , 60 mg (75%) of compound (-)-5l- α was obtained as a colourless oil after flash chromatography (hexanes/ethyl acetate 5:1). [α]_D = -147 (*c* 1.1, CHCl₃). NMR data: δ_H (CDCl₃) 1.57 (d, 3H, *J* = 6.8 Hz, PhCHCH₃), 1.83 (s, 3H, CH₃), 2.26 (dd, 1H, *J* = 13.1, 17.5 Hz, H5), 2.71 (bd, 1H, *J* = 17.5 Hz, H5'), 3.95 (m, 1H, H6), 5.60 (m, 2H, NCHPh, H7), 5.88 (d, 1H, *J* = 1.2 Hz, H3), 6.11 (q, 1H, *J* = 6.8 Hz, H8), 7.26 (m, 10H, Ar). δ_C (CDCl₃) 167.5 (C2), 142.8, 140.0, 139.3, 132.2, 131.5, 128.8, 128.4, 127.6, 127.6, 126.9, 124.4, 120.5, 51.2, 41.7, 39.5, 26.1, 16.1. . IR (CHCl₃, cm⁻¹): ν 1739 (C=O), 1650, 1600. Anal. Calcd for C₂₂H₂₃NO: C, 83.24; H, 7.30; N, 4.41. Found: C, 83.17; H, 7.40; N, 4.55.

Azocin-2-one (+)-5l- β . From 30 mg (0.09 mmol) of compound (+)-4b- β , 25 mg (83%) of compound (+)-5l- β was obtained as a colourless oil after flash chromatography (hexanes/ethyl acetate 5:1). [α]_D = +166 (*c* 1.5, CHCl₃). NMR data: δ_H (CDCl₃) 1.62 (d, 3H, *J* = 6.8 Hz, PhCHCH₃), 1.82 (s, 3H, CH₃), 2.18 (dd, 1H, *J* = 13.2, 16.9 Hz, CHH), 2.57 (bd., 1H, *J* = 16.9 Hz, CHH), 3.41 (m, 1H, CH-Ph), 5.48 (t, 1H, *J* = 9.1 Hz, CH=CH-N), 5.83 (s, 1H, NCHPh), 6.09–6.19 (m, 2H, CH₃C=CH, CH=CH-N), 6.62 (m, 2H, Ar), 7.16–7.44 (m, 8H, Ar). δ_C (CDCl₃) 167.5 (C=O), 142.5, 132.2, 128.4, 127.7, 127.4, 126.9, 126.5, 126.2, 123.6, 122.2,

121.0, 120.4, 51.7, 41.0, 39.0, 26.3, 16.0. IR (CHCl₃, cm⁻¹): v 1740 (C=O), 1650, 1605. Anal. Calcd for C₂₂H₂₃NO: C, 83.24; H, 7.30; N, 4.41. Found: C, 83.19; H, 7.23; N, 4.22.

Acknowledgements

Support for this work by the DGI-MEC (CTQ2006-10292), Comunidad Autónoma de Madrid (CCG-07-UCM/PPQ-2308), and Universidad Complutense de Madrid (Grant GR74/07) are gratefully acknowledged.

References

1. For selected examples, see: Basil, B.; Coffee, E. C. J.; Gell, D. L.; Maxwell, D. R.; Sheffield, D. J.; Wooldridge, K. R. H. *J. Med. Chem.* **1970**, *13*, 403. Klayman, D. L.; Scovill, J. P.; Bartosevich, J. F.; Mason, C. J. *J. Med. Chem.* **1979**, *22*, 1367. Vedejs, E.; Galante, R. J.; Goekjian, P. G. *J. Am. Chem. Soc.* **1998**, *120*, 3613.
2. Pflantz, R.; Tielmann, P.; Rössle, M.; Hoenke, C.; Christoffers, J. *Eur. J. Org. Chem.* **2007**, 3227. Pearson , W. H.; Lee , I. Y.; Mi , Y.; Stoy, P. *J. Org. Chem.* **2004** , *69*, 9109. Arya, P.; Couve-Bonnaire, S.; Durieux, P.; Laforce, D.; Kumar, R.; Leek, D. M. *J. Comb. Chem.* **2004**, *6*, 735. Hansen, L. K.; Størmer, F. C.; Petersen, D.; Aasen, A. J. *Acta Crystallogr. Sec. E* **2001**, *57*, 909.
3. Bergemann, S.; Brecht, R.; Büttner, F.; Guenard, D.; Gust, R.; Seitz, G.; Stubbs, M. T.; Thoret, S. *Bioorg. Med. Chem.* **2003**, *11*, 1269. Baudoin, O.; Cesario, M.; Guenard, D.; Gueritte, F. *J. Org. Chem.* **2002**, *67*, 1199. Brecht, R.; Seitz, G.; Guenard, D.; Thoret, S. *Bioorg. Med. Chem.* **2000**, *8*, 557. Berg, U.; Bladh, H.; Svensson, C.; Wallin, M. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 2771. Schoen, W. R.; Pisano, J. M.; Prandergast, K.; Wyvratt, M. J.; Fisher, M. H.; Cheng, K.; Chan, W. W.-S.; Butler, B.; Smith, R. G.; Ball, R. G. *J. Med. Chem.* **1994**, *37*, 897. Watthey, J. W. H.; Stanton, J. L.; Desai, M.; Babiarz, J. E.; Finn, B. M. *J. Med. Chem.* **1985**, *28*, 1511.
4. Kaul, R.; Surprenant, S.; Lubell, W. D. *J. Org. Chem.* **2005**, *70*, 4901. Creighton, C. J.; Leo, G. C.; Du, Y.; Reitz, A. B. *Bioorg. Med. Chem.* **2004**, *12*, 4375. Derrer, S.; Davies, J. E.; Holmes, A. B. *J. Chem. Soc., Perkin Trans. 1* **2000**, 2943. Derrer, S.; Davies, J. E.; Holmes, A. B. *J. Chem. Soc., Perkin Trans. 1* **2000**, 2957. Derrer, S.; Feeder, N.; Teat, S. J.; Davies, J. E.; Holmes, A. B. *Tetrahedron Lett.* **1998**, *39*, 9309.
5. For reviews, see: Galli, C.; Mandolini, L. *Eur. J. Org. Chem.* **2000**, 3117. Illuminati, G.; Mandolini, L. *Acc. Chem. Res.* **1981**, *14*, 95.
6. For reviews, see: Nubbemeyer, U. *Synlett* **2003**, 961. Allin, S. M.; Baird, R. D. *Curr. Org. Chem.* **2003**, *5*, 395. Hill, R. K. *Comprehensive Organic Synthesis*, Pergamon: Oxford, 1991, Vol.5, p 785. Bronson, J. J.; Danheiser, R. L. *Comprehensive Organic Synthesis*, Pergamon: Oxford, 1991, Vol. 5, p 999.

7. See, for example: Setti, E. L.; Micetich, R. G. *Curr. Med. Chem.* **1998**, *5*, 101. *The Organic Chemistry of β -Lactams*; Georg, G. I., Ed.; VCH: New York, 1993. Neuhaus, F. C.; Georgeopapadakou, N. H. In *Emerging Targets in Antibacterial and Antifungal Chemotherapy*; Sutcliffe, J.; Georgeopapadakou, N. H., Eds.; Chapman and Hall: New York, 1992. *The Chemistry of β -Lactams*; Page, M. I., Ed.; Chapman and Hall: London, 1992.
8. Some of the more notable advances concern the development of mechanism-based serine protease inhibitors of elastase, cytomegalovirus protease, thrombin, prostate specific antigen, and cell metastasis and as inhibitors of acyl-CoA cholesterol acyl transferase. For reviews, see: Veinberg, G.; Vorona, M.; Shestakova, I.; Kanepe, I.; Lukevics, E. *Curr. Med. Chem.* **2003**, *10*, 1741. Clader, J. W. *J. Med. Chem.* **2004**, *47*, 1. For selected examples, see: Kvaerno, L.; Ritter, T.; Werder, M.; Hauser, H.; Carreira, E. M. *Ang. Chem. Int. Ed.* **2004**, *43*, 4653. Burnett, D. A. *Curr. Med. Chem.* **2004**, *11*, 1873. (e) Page, M. I.; Laws, A. P. *Tetrahedron* **2000**, *56*, 5631. Haley, T. M.; Angier, S. J.; Borthwick, A. D.; Singh, R.; Micetich, R. G. *Drugs* **2000**, *3*, 512.
9. Rothstein, J. D.; Patel, S.; Regan, M. R.; Haenggeli, C.; Huang, Y. H.; Bergles, D. E.; Jin, L.; Hoberg, M. D.; Vidensky, S.; Chung, D. S.; Toan, S. V.; Bruijn, L. I.; Su, Z.-z.; Gupta, P.; Fisher, P. B. *Nature* **2005**, *433*, 73.
10. For reviews, see: Alcaide, B.; Almendros, P.; Aragoncillo, C. *Chem. Rev.* **2007**, *107*, 4437. Alcaide, B.; Almendros, P. *Curr. Med. Chem.* **2004**, *11*, 1921. Deshmukh, A. R. A. S.; Bhawal, B. M.; Krishnaswamy, D.; Govande, V. V.; Shinkre, B. A.; Jayanthi, A. *Curr. Med. Chem.* **2004**, *11*, 1889. Alcaide, B.; Almendros, P. *Synlett* **2002**, 381. Palomo, C.; Aizpurua, J. M.; Ganboa, I.; Oiarbide, M. *Synlett* **2001**, 1813. Alcaide, B.; Almendros, P. *Org. Prep. Proced. Int.* **2001**, *33*, 315. Palomo, C.; Aizpurua, J. M.; Ganboa, I.; Oiarbide, M. *Amino-acids*, **1999**, *16*, 321. Ojima, I.; Delaloge, F. *Chem. Soc. Rev.* **1997**, *26*, 377. Ojima, I. *Adv. Asym. Synth.* **1995**, *1*, 95. Manhas, M. S.; Wagle, D. R.; Chiang, J.; Bose, A. K. *Heterocycles* **1988**, *27*, 1755.
11. For a thermal *cis/trans* isomerization in 2-azetidinones, see: Alcaide, B.; Almendros, P.; Salgado, N. R.; Rodríguez-Vicente, A. *J. Org. Chem.*, **2000**, *65*, 4453. For thermal fragmentations of β -lactams, see: Paquette, L. A.; Wyvratt, M. J.; Allen Jr, G. R. *J. Am. Chem. Soc.* **1970**, *92*, 1763. Kappe, C. O.; Kollenz, G.; Netsch, K.-P.; Leung-Toung, R.; Wentrup, C. *Chem. Commun.* **1992**, 488.
12. See, for example: Alcaide, B.; Almendros, P.; Martínez del Campo, T. *Chem. Eur. J.* **2008**, *14*, 7756. Alcaide, B.; Almendros, P.; Carrascosa, R.; Redondo, M. C. *Chem. Eur. J.* **2008**, *14*, 637. Alcaide, B.; Almendros, P.; Martínez del Campo, T. *Angew. Chem. Int. Ed.* **2007**, *46*, 6684. Alcaide, B.; Almendros, P.; Cabrero, G.; Ruiz, M. P. *Chem. Commun.* **2007**, 4788. Alcaide, B.; Almendros, P.; Aragoncillo, C., Redondo, M. C. *J. Org. Chem.* **2007**, *72*, 1604. Alcaide, B.; Almendros, P.; Martínez del Campo, T. *Angew. Chem. Int. Ed.* **2006**, *45*, 4501. Alcaide, B.; Almendros, P.; Alonso, J. M. *Chem. Eur. J.* **2006**, *12*, 2874. Alcaide, B.; Almendros, P.; Aragoncillo, C.; Redondo, M. C.; Torres, M. R. *Chem. Eur. J.* **2006**, *12*, 1539.

13. For a preliminary communication of a part of this work, see: Alcaide, B.; Rodríguez-Ranera, C.; Rodríguez-Vicente, A. *Tetrahedron Lett.* **2001**, *42*, 3081.
14. Alcaide, B.; Almendros, P. *Chem. Soc. Rev.* **2001**, *30*, 226.
15. Manhas, M. S.; Ghosh, M.; Bose, A. K. *J. Org. Chem.*, **1990**, *55*, 575, and references cited therein.
16. Palomo, C.; Cossio, F. P.; Arrieta, A.; Odriozola, J. M.; Oiarbide, M.; Ontoria, J. M. *J. Org. Chem.* **1989**, *54*, 5736 and references cited therein.
17. Berson, J. A.; Dervan, P. B.; Malherbe, R.; Jenkins, J. A. *J. Am. Chem. Soc.* **1976**, *98*, 5937 and references cited therein.